CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides specifically designed to stimulate Toll-like receptor 9. TLR9 is expressed on human plasmacytoid dendritic cells and B cells and triggers an innate immune response characterized by the production of Th1 and pro-inflammatory cytokines. This chapter reviews recent progress in understanding the mechanism of action of CpG ODN and provides an overview of human clinical trial results using CpG ODN to improve vaccines for the prevention/treatment of cancer, allergy, and infectious disease.
CITATION STYLE
Kayraklioglu, N., Horuluoglu, B., & Klinman, D. M. (2021). CpG Oligonucleotides as Vaccine Adjuvants. In Methods in Molecular Biology (Vol. 2197, pp. 51–85). Humana Press Inc. https://doi.org/10.1007/978-1-0716-0872-2_4
Mendeley helps you to discover research relevant for your work.